SCHEDULE: RA Capital Boosts Solid Biosciences Stake to 9.9%

RA Capital Management and its affiliates have increased their beneficial ownership in Solid Biosciences Inc. to 9.9% through recent open market purchases.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (Reporting Persons) filed Amendment No. 10 to their Schedule 13D.
• The Reporting Persons collectively beneficially own 7,997,510 shares of Solid Biosciences Inc. common stock, representing 9.9% of the outstanding shares.
• This ownership includes 5,673,193 shares held directly by RA Capital Healthcare Fund, L.P., 109,661 shares by RA Capital Nexus Fund, L.P., 28,569 shares by a separately managed account, and pre-funded warrants exercisable for up to 3,722,085 shares.
• The pre-funded warrants contain a beneficial ownership blocker, which precludes exercise to the extent that, following exercise, the Fund, together with its affiliates, would own more than 9.99% of the common stock outstanding.
• The percentage of ownership is calculated based on 77,869,071 shares outstanding as of August 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 12, 2025, plus shares issuable upon exercise of the Pre-Funded Warrants exercisable within 60 days.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investor, RA Capital Management, has increased its stake in Solid Biosciences Inc. through open market purchases, suggesting a positive view on the company's prospects. The maintenance of a substantial beneficial ownership (9.9%) further reinforces this positive sentiment.

Positives

• RA Capital Healthcare Fund, L.P. made several open market purchases of Solid Biosciences common stock in June and July 2025, indicating continued investment and confidence in the company.
• The aggregate beneficial ownership of 9.9% by a prominent investment firm like RA Capital Management signals a significant stake and potential long-term interest in Solid Biosciences.

Risks

• The Pre-Funded Warrants include a Beneficial Ownership Blocker, which limits the exercise of warrants if it would result in beneficial ownership exceeding 9.99% of the common stock outstanding, potentially restricting full conversion of warrants.

Future Outlook

This filing, an amendment to a Schedule 13D, primarily discloses changes in beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the company's future operations or financial performance.

Industry Context

This filing reflects an institutional investor's increased stake in a biotechnology company, a common activity in the sector where strategic investments by specialized funds can signal confidence in a company's pipeline or market position. It does not provide broader industry trend analysis.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership and does not contain information for direct comparison to industry-specific operational or financial benchmarks.
• The investment firm's decision to increase its stake suggests a positive internal assessment relative to its investment criteria for biotechnology companies.

Stakeholder Impact

• Shareholders: The increased stake by a prominent institutional investor like RA Capital Management could be viewed positively, potentially signaling confidence in the company's value proposition.
• Employees, Customers, Suppliers, Creditors: This filing primarily concerns ownership structure and does not directly impact these stakeholder groups.

Next Steps

• The filing does not specify future actions or milestones for Solid Biosciences Inc. or the Reporting Persons beyond the ongoing management of their investment.

Key Dates

Recommendation

RA Capital Management, a sophisticated institutional investor, has increased its stake in Solid Biosciences Inc. through open market purchases, bringing its total beneficial ownership to 9.9%. This action suggests continued confidence in the company's long-term prospects. While this is a positive signal, the filing is a disclosure of ownership changes rather than a comprehensive financial report. Investors should consider this increased institutional interest as a supportive factor, but combine it with a thorough analysis of Solid Biosciences' operational performance, pipeline, and market conditions before making definitive investment decisions. Therefore, a 'hold' recommendation is appropriate, encouraging existing investors to maintain their positions while new investors conduct further due diligence.

Keywords

Solid Biosciences, RA Capital Management, Schedule 13D, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Biotechnology Investment, Institutional Investor